Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

NovartisNovartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies.

The licensed biomaterial systems aim to overcome barriers that have hampered traditional cancer vaccines, including their limited duration of action and lack of targeting to specific cancer cells. Through many years' work, researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), the Wyss Institute, and Dana-Farber have engineered the biomaterial systems with an aim to provide sustained delivery of immunotherapies and target specific types of cancer. Novartis will further collaborate with the team at the Wyss Institute to advance development of the biomaterial systems, investigating their use to deliver agents from its broad and deep portfolio of second-generation immunotherapies.

"Our collaborators have combined the fields of immuno-oncology and material science to develop novel platforms for delivering immunotherapies to combat cancer," said Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR). "We look forward to collaborating with the Wyss Institute to further develop this technology in conjunction with our growing immunotherapy portfolio."

The licensing agreement with Harvard's Office of Technology Development and the collaboration with the Wyss Institute support Novartis' efforts to develop combination immunotherapy regimens. New immunotherapies have benefited subsets of cancer patients, presenting opportunities to develop new immuno-oncology treatment strategies to help more patients [1]. Novartis is developing combination immunotherapies in clinical trials.

The implantable and injectable systems are made of biodegradable materials that assemble into porous, three-dimensional structures. In lab experiments, the systems release cell-recruiting factors to attract host dendritic cells and present tumor antigens to those specialized immune cells, intending to bolster immune responses to cancer [2]. While these systems have yet not been proven in human clinical trials, they hold great promise because of their potential to serve as engineered microenvironments to educate the immune system about cancer and initiate immune responses against tumors over a sustained period of time.

The technologies licensed under this agreement for target-specific applications are owned or co-owned by Harvard University, Dana-Farber, and the University of Michigan.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

1. Nat Rev Cancer. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Gotwals P. et. al. 2017.
2. Nat Commun. Injectable cryogel-based whole-cell cancer vaccines. Bencherif S.A. et al. 2015.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...